{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Seattle&page=30&state=Washington",
    "query": {
      "state": "Washington",
      "city": "Seattle",
      "page": 30
    },
    "page_size": 10
  },
  "pagination": {
    "page": 30,
    "page_size": 10,
    "total_count": 11406,
    "total_pages": 1141,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Seattle&page=31&state=Washington&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Seattle&page=29&state=Washington&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-05T17:17:51.592Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00458601",
      "title": "Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Glioma"
      ],
      "interventions": [
        {
          "name": "CDX-110 with GM-CSF",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celldex Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 82,
      "start_date": "2007-08",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2018-01-16",
      "last_synced_at": "2026-11-05T17:17:51.592Z",
      "location_count": 34,
      "location_summary": "Orange, California • San Francisco, California • Stanford, California + 22 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00458601"
    },
    {
      "nct_id": "NCT00147628",
      "title": "Assessment Of Sildenafil On Erectile Function And Intercourse Satisfaction And To Validate A New Subject Questionnaire",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Impotence"
      ],
      "interventions": [
        {
          "name": "sildenafil citrate",
          "type": "DRUG"
        },
        {
          "name": "placebo for sildenafil citrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 209,
      "start_date": "2005-11",
      "completion_date": "2006-09",
      "has_results": false,
      "last_update_posted_date": "2021-02-01",
      "last_synced_at": "2026-11-05T17:17:51.592Z",
      "location_count": 20,
      "location_summary": "Huntsville, Alabama • San Diego, California • Aurora, Colorado + 17 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00147628"
    },
    {
      "nct_id": "NCT05622682",
      "title": "Vaccine Immune Recovery After Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Lymphoblastic Leukemia, Pediatric"
      ],
      "interventions": [
        {
          "name": "Observational only: Serology and flow cytometry for ALL cohort participants",
          "type": "OTHER"
        },
        {
          "name": "Observational only: Infection rates",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "31 Years",
        "sex": "ALL",
        "summary": "3 Years to 31 Years"
      },
      "enrollment_count": 89,
      "start_date": "2022-09-28",
      "completion_date": "2025-11-30",
      "has_results": true,
      "last_update_posted_date": "2026-01-26",
      "last_synced_at": "2026-11-05T17:17:51.592Z",
      "location_count": 6,
      "location_summary": "Chicago, Illinois • Grand Rapids, Michigan • Philadelphia, Pennsylvania + 3 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05622682"
    },
    {
      "nct_id": "NCT00100659",
      "title": "PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Pegylated Interferon/ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "5 Years to 18 Years"
      },
      "enrollment_count": 114,
      "start_date": "2004-12",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2018-10-24",
      "last_synced_at": "2026-11-05T17:17:51.592Z",
      "location_count": 11,
      "location_summary": "San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 8 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00100659"
    },
    {
      "nct_id": "NCT04392154",
      "title": "Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Lebrikizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1153,
      "start_date": "2020-06-15",
      "completion_date": "2025-04-22",
      "has_results": true,
      "last_update_posted_date": "2025-11-05",
      "last_synced_at": "2026-11-05T17:17:51.592Z",
      "location_count": 160,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 124 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04392154"
    },
    {
      "nct_id": "NCT02661451",
      "title": "Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Aortic Valve Stenosis"
      ],
      "interventions": [
        {
          "name": "SAPIEN 3 THV",
          "type": "DEVICE"
        },
        {
          "name": "Optimal Heart Failure Therapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "BIOLOGICAL"
      ],
      "sponsor": "Cardiovascular Research Foundation, New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 178,
      "start_date": "2016-09",
      "completion_date": "2025-02",
      "has_results": false,
      "last_update_posted_date": "2024-11-27",
      "last_synced_at": "2026-11-05T17:17:51.592Z",
      "location_count": 46,
      "location_summary": "Chandler, Arizona • La Jolla, California • Los Angeles, California + 37 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02661451"
    },
    {
      "nct_id": "NCT03584282",
      "title": "Interventions to Improve the HIV PrEP Cascade Among Methamphetamine Users",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV/AIDS",
        "Adherence, Medication",
        "Drug Use"
      ],
      "interventions": [
        {
          "name": "Text Messaging",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Peer Navigation",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2018-07-11",
      "completion_date": "2022-06-30",
      "has_results": true,
      "last_update_posted_date": "2024-06-05",
      "last_synced_at": "2026-11-05T17:17:51.592Z",
      "location_count": 2,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03584282"
    },
    {
      "nct_id": "NCT01594723",
      "title": "A Study of LY2784544 in Participants With Myeloproliferative Neoplasms",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms, Hematologic"
      ],
      "interventions": [
        {
          "name": "120 mg LY2784544",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2012-05-22",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-11-05T17:17:51.592Z",
      "location_count": 23,
      "location_summary": "Rogers, Arkansas • Burbank, California • Norwalk, Connecticut + 19 more",
      "locations": [
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Norwalk",
          "state": "Connecticut"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01594723"
    },
    {
      "nct_id": "NCT04068896",
      "title": "Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Metastatic Castration-resistant Prostate Cancer",
        "Bladder Cancer",
        "Melanoma",
        "Non-small Cell Lung Cancer",
        "Colorectal Cancer",
        "Gastric Cancer",
        "Esophageal Cancer",
        "Ovarian Cancer",
        "Head Neck Squamous Cell Carcinoma",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "NGM120 30mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NGM120 100mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NGM120 30mg with Gemcitabine and Abraxane",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NGM120 100mg with Gemcitabine and Abraxane",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NGM120 100mg Q3W",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "NGM Biopharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2019-10-16",
      "completion_date": "2024-01-08",
      "has_results": true,
      "last_update_posted_date": "2025-05-29",
      "last_synced_at": "2026-11-05T17:17:51.592Z",
      "location_count": 20,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04068896"
    },
    {
      "nct_id": "NCT06952803",
      "title": "A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Saruparib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone + Prednisolone/Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Androgen Deprivation Therapy (ADT)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 700,
      "start_date": "2025-08-06",
      "completion_date": "2036-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-11-05T17:17:51.592Z",
      "location_count": 45,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 40 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06952803"
    }
  ]
}